TRCT
AVBP icon

Tower Research Capital (TRC)’s ArriVent BioPharma AVBP Stock Holding History

Tower Research Capital (TRC)’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$57.7K Buy
2,500
+130
+5% +$2.94K ﹤0.01% 2615
2025
Q4 		$47.7K Buy
2,370
+1,087
+85% +$22.6K ﹤0.01% 2455
2025
Q3 		$23.7K Sell
1,283
-5,386
-81% -$106K ﹤0.01% 3153
2025
Q2 		$145K Buy
6,669
+5,676
+572% +$118K ﹤0.01% 2075
2025
Q1 		$18.4K Sell
993
-606
-38% -$14.8K ﹤0.01% 3048
2024
Q4 		$42.6K Buy
1,599
+1,416
+774% +$40.7K ﹤0.01% 2655
2024
Q3 		$4.3K Sell
183
-1,309
-88% -$29.7K ﹤0.01% 4597
2024
Q2 		$27.7K Buy
1,492
+888
+147% +$15.8K ﹤0.01% 3549
2024
Q1 		$10.8K Buy
+604
New +$12.2K ﹤0.01% 3651

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Tower Research Capital (TRC)'s AVBP Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its ArriVent BioPharma (AVBP) stake by 5.5% in Q1 2026, buying an estimated $2.94K and bringing the position to 2,500 shares worth $57.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2615.

Tower Research Capital (TRC) first reported a position in AVBP in Q1 2024 and has held it in 9 quarters since. The position peaked at $145K in Q2 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Tower Research Capital (TRC) held 2,500 shares of ArriVent BioPharma worth $57.7K as of Q1 2026.
  • Tower Research Capital (TRC) bought 130 ArriVent BioPharma shares in Q1 2026, an estimated $2.94K.
  • ArriVent BioPharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2615 holding.
  • Tower Research Capital (TRC) first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 9 quarters since.
  • Tower Research Capital (TRC)'s ArriVent BioPharma position peaked at $145K in Q2 2025.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.